Boston Scientific BSX
Boston Scientific Corp · NYSE · Surgical & Medical Instruments & Apparatus
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 25, 2026 | Susan E. Morano director | Bought | 2,040 | $49.22 | $100,408 |
| Aug. 5, 2026 | David C. Habiger director | Bought | 2,100 | $47.59 | $99,937 |
| Aug. 4, 2026 | David C. Habiger director | Bought | 140 | $48.59 | $6,802 |
| Aug. 3, 2026 | David C. Habiger director | Bought | 1,042 | $48.07 | $50,084 |
| Aug. 3, 2026 | Michael F. Mahoney Chairman, President & CEO, director | Bought | 186,240 | $48.33 | $9.00 million |
| July 31, 2026 | Edward J. Ludwig director | Bought | 5,000 | $45.48 | $227,400 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 18 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedBoston Scientific Q3 2026 adjusted EPS of $0.73 beats $0.72 consensus on $5.138 billion sales, but Q4 and full-year adjusted EPS guidance falls below consensus
Departure/appointment of directors or officers · Other events · Financial statements and exhibits
Departure/appointment of directors or officers
Material cybersecurity incident
Other events